Table 2.
Study design
| Days 1–8 | 9–18 | 19–26 | 27–36 | 37–44 | |
|---|---|---|---|---|---|
| Cassette | Cassette | Cassette | |||
| Cohort 1, N = 20 | RIF 10 mg q.d. | RIF 75 mg q.d. | |||
| Cohort 2, N = 20 | RIF 2 mg q.d. | RIF 600 mg q.d. | |||
| Probe drug cassette | Dose | Abbreviation | P450/transporter | Cassette day | |
| Dabigatran etexilate | 75 mg | DE | P‐gp | 1 | |
| Pravastatin | 20 mg | PRA | OATP | 3 | |
| Rosuvastatin | 10 mg | ROS | OATP/BCRP | 5 | |
| Cocktail | Midazolam | 2 mg | MDZ | CYP3A | 7 |
| Tolbutamide | 500 mg | TOL | CYP2C9 | ||
| Caffeine | 200 mg | CAF | CYP1A2 | ||
*DE was analyzed as total dabigatran (TDAB), the sum of conjugated and unconjugated active species.